0
     

Report Added
Report already added
Sarcopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Sarcopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body’s ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 1, 21, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sarcopenia - Overview
Sarcopenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sarcopenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sarcopenia - Companies Involved in Therapeutics Development
AAVogen Inc
Anagenesis Biotechnologies SAS
ARMGO Pharma Inc
Berg LLC
Bioleaders Corp
Biophytis SA
Daewoong Pharmaceutical Co Ltd
Dystrogen Therapeutics SA
Elevian Inc
Elixir Pharma Co Ltd
Encell Co Ltd
Faraday Pharmaceuticals Inc
Gerologix Inc
Helixmith Co Ltd
Juvena Therapeutics Inc
Keren Therapeutics
Klotho Therapeutics Inc
KSbitugen Co Ltd
Lipocine Inc
MedAvail Holdings Inc
MyMD Pharmaceuticals, Inc
Neurotune AG
NMD Pharma AS
Oncocross Co Ltd
OPKO Health Inc
Pephexia Therapeutics ApS
PhaseBio Pharmaceuticals Inc
PRG S&Tech Inc
Ridgeline Therapeutics LLC
ST Pharm Co Ltd
Vibe Pharmaceuticals LLC
Sarcopenia - Drug Profiles
Antibody - Drug Profile
Product Description
Mechanism Of Action
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BIO-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BLSM-22 - Drug Profile
Product Description
Mechanism Of Action
BLSM-32 - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit SARM1 for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
Drugs for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
DWP-458 - Drug Profile
Product Description
Mechanism Of Action
EN-001 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Muscular Atrophy, Sarcopenia and Traumatic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
JUV-191 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Kinase Derivatives - Drug Profile
Product Description
Mechanism Of Action
KSB-10104 - Drug Profile
Product Description
Mechanism Of Action
KSB-10201 - Drug Profile
Product Description
Mechanism Of Action
KSB-10301 - Drug Profile
Product Description
Mechanism Of Action
KT-101 - Drug Profile
Product Description
Mechanism Of Action
KT-102 - Drug Profile
Product Description
Mechanism Of Action
KT-103 - Drug Profile
Product Description
Mechanism Of Action
LPCN-1148 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MyMD-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NMDP-05 - Drug Profile
Product Description
Mechanism Of Action
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
OC-504 - Drug Profile
Product Description
Mechanism Of Action
OC-514 - Drug Profile
Product Description
Mechanism Of Action
OPK-88004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PB-1023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide for Cachexia and Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
PRG-S-3 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Klotho Replacement for Kidney Disease, Aging, Breast Cancer, Cognitive Impairment, Type 2 Diabetes and Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
RJx-01 - Drug Profile
Product Description
Mechanism Of Action
RT-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Cyclooxygenase 2 for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit IDO1 for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit JAK3 for Cachexia, Dermatitis, Rheumatoid Arthritis and Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
History of Events
sodium iodide - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
trimera - Drug Profile
Product Description
Mechanism Of Action
History of Events
ubidecarenone - Drug Profile
Product Description
Mechanism Of Action
VB-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Sarcopenia - Dormant Projects
Sarcopenia - Discontinued Products
Sarcopenia - Product Development Milestones
Featured News & Press Releases
Feb 25, 2022: Oncocross begins clinical trial for AI-developed drug for sarcopenia
Jan 05, 2022: MyMD Pharmaceuticals announces issuance of new U.S. patent covering MYMD-1 in a method of treating sarcopenia
Dec 16, 2021: Biophytis to meet with FDA to advance Sarconeos (BIO101) development in sarcopenia from phase 2 to phase 3
Oct 06, 2021: Biophytis to host virtual KOL event on Sarconeos (BIO101) on its lead projects in COVID-19 and Sarcopenia
Oct 04, 2021: Biophytis announces promising full results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 - October 2, 2021
Sep 29, 2021: Biophytis to present full results from the SARA-INT Phase 2b trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 - October 2, 2021
Aug 02, 2021: Biophytis announces top line results of SARA-INT phase 2 study with Sarconeos (BIO101) in sarcopenia
Jun 30, 2021: Results of Biophytis SARA-INT phase 2 trial with Sarconeos (BIO101) in sarcopenia will be released by August 2021
Dec 16, 2020: Biophytis - Last patient completes final visit in SARA-INT, a Phase 2 clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia
Dec 14, 2020: Biophytis presents SARA-OBS study results at the annual conference of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)
Aug 28, 2020: Biophytis provides an update on SARA-INT, a phase 2b clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia
Mar 24, 2020: Biophytis completes recruitment of SARA-INT phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia
Mar 03, 2020: Biophytis to present the preliminary results of SARA-OBS and its impact on SARA-INT, the phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France
Feb 11, 2020: Biophytis - Protocol amendment of SARA-INT, a phase 2b clinical trial of Sarconeos (BIO101) in sarcopenia, cleared by FDA and AFMPS
Dec 12, 2019: Biophytis to attend Biotech Showcase 2020 in San Francisco, USA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sarcopenia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Sarcopenia - Pipeline by AAVogen Inc, 2022
Sarcopenia - Pipeline by Anagenesis Biotechnologies SAS, 2022
Sarcopenia - Pipeline by ARMGO Pharma Inc, 2022
Sarcopenia - Pipeline by Berg LLC, 2022
Sarcopenia - Pipeline by Bioleaders Corp, 2022
Sarcopenia - Pipeline by Biophytis SA, 2022
Sarcopenia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Sarcopenia - Pipeline by Dystrogen Therapeutics SA, 2022
Sarcopenia - Pipeline by Elevian Inc, 2022
Sarcopenia - Pipeline by Elixir Pharma Co Ltd, 2022
Sarcopenia - Pipeline by Encell Co Ltd, 2022
Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, 2022
Sarcopenia - Pipeline by Gerologix Inc, 2022
Sarcopenia - Pipeline by Helixmith Co Ltd, 2022
Sarcopenia - Pipeline by Juvena Therapeutics Inc, 2022
Sarcopenia - Pipeline by Keren Therapeutics, 2022
Sarcopenia - Pipeline by Klotho Therapeutics Inc, 2022
Sarcopenia - Pipeline by KSbitugen Co Ltd, 2022
Sarcopenia - Pipeline by Lipocine Inc, 2022
Sarcopenia - Pipeline by MedAvail Holdings Inc, 2022
Sarcopenia - Pipeline by MyMD Pharmaceuticals, Inc, 2022
Sarcopenia - Pipeline by Neurotune AG, 2022
Sarcopenia - Pipeline by NMD Pharma AS, 2022
Sarcopenia - Pipeline by Oncocross Co Ltd, 2022
Sarcopenia - Pipeline by OPKO Health Inc, 2022
Sarcopenia - Pipeline by Pephexia Therapeutics ApS, 2022
Sarcopenia - Pipeline by PhaseBio Pharmaceuticals Inc, 2022
Sarcopenia - Pipeline by PRG S&Tech Inc, 2022
Sarcopenia - Pipeline by Ridgeline Therapeutics LLC, 2022
Sarcopenia - Pipeline by ST Pharm Co Ltd, 2022
Sarcopenia - Pipeline by Vibe Pharmaceuticals LLC, 2022
Sarcopenia - Dormant Projects, 2022
Sarcopenia - Discontinued Products, 2022

List of Figures
Number of Products under Development for Sarcopenia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Sarcopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027

Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027

Patient Monitoring Devices Market by Product (EEG, MEG, TCD, Pulse Oximeter, Spirometer, Fetal Monitor, Temperature Monitor, MCOT, ECG, ICP, ILRs, Multi-parameter Monitoring, Weight Monitoring), End-User (Hospital, ASCs) - Global Forecast to 2027

Patient Monitoring Devices Market by Product (EEG, MEG, TCD, Pulse Oximeter, Spirometer, Fetal Monitor, Temperature Monitor, MCOT, ECG, ICP, ILRs, Multi-parameter Monitoring, Weight Monitoring), End-User (Hospital, ASCs) - Global Forecast to 2027

US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028

US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028

Asia Pacific Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

Asia Pacific Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

Europe Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

Europe Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

North America Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

North America Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity